Chemotherapy for early stage non-small cell lung cancer

Lung Cancer

Volumn 34, Issue SUPPL. 3, 2001, Pages 49-52

  Kris, Mark G ^a   Azzoli, Christopher G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Adjuvant therapy; Early stage; Neoadjuvant therapy; Non small cell lung cancer; Preoperative therapy; ras; Thoracic surgery; Tumor vaccine; ZD1839

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; GEFITINIB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MITOMYCIN; PROTEIN TYROSINE KINASE; TEGAFUR; TUMOR VACCINE; UFT; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ANTINEOPLASTIC ACTIVITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL;

EID: 0035195436     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(01)00372-5     Document Type: Conference Paper

References (22)

1. Survival in early-stage non-small cell lung cancer
2. Sites of recurrence in resected Stage I non-small cell lung cancer: A guide for future studies
3. Cancer recurrence after resection: T1N0 non-small cell lung cancer
4. Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease
5. Incidence of local recurrence and second primary tumors in resected stage I lung cancer
6. Preresectional chemotherapy in Stage IIIA non-small cell lung cancer: a 7-year assessment of a randomized controlled trial
7. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell cancer
8. Induction chemotherapy before surgery for early-stage lung cancer: a novel approach
9. Phase III trial of neo-adjuvant chemotherapy (NCT) in resectable stage I (except T1N0), II, IIIa non-small cell lung cancer (NSCLC): the French experience
10. Adjuvant chemotherapy after radical surgery for non-small-cell lung cancer: A randomized study
11. Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completed resected stage I non-small-cell lung cancer
12. Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery
13. Differential expression of the epidermal growth factors receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung
14. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression
15. Recurrence and death in non-small cell lung carcinomas: a prognostic model using pathological parameters, microvessel count, and gene protein products
16. Continuous administration of ZD (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TK1) in patients with five selected tumor types: evidence of activity and good tolerability
17. Intermittent oral ZD (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (Egfr-Tki), shows evidence of good tolerability and activity: final results from a Phase I study
18. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by co-administration of ZD (Iressa), an inhibitor of EGFR tyrosine kinase
19. K-ras gene point mutation: a stable tumor marker in non-small cell lung carcinoma
20. Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients